Victor Fariwa, MD
Internal Medicine · Deal, NJNPI 1023028354
Payments from drug & device makers
Across 129 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$353
- Heartflow, Inc.$247
- Paratek Pharmaceuticals, Inc.$164
- Amarin Pharma, Inc.$146
- AstraZeneca$119
- Johnson & Johnson$115
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,23295%
- Education$1065%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $353 |
| Heartflow, Inc. | 12 | $247 |
| Paratek Pharmaceuticals, Inc. | 9 | $164 |
| Amarin Pharma, Inc. | 20 | $146 |
| AstraZeneca | 6 | $119 |
| Johnson & Johnson | 5 | $115 |
| Lilly USA, LLC | 5 | $112 |
| Novartis | 4 | $69 |
| Novo Nordisk | 3 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Exact Sciences | 3 | $69 |
| Kowa Pharmaceuticals America, Inc. | 5 | $67 |
| Genentech USA, Inc. | 3 | $64 |
| GSK | 2 | $58 |
| Amgen(2 entities) | 2 | $46 |
| Pfizer | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Hikma Pharmaceuticals USA | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Nevro Corp. | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 2 | $28 |
| Mylan Specialty L.p. | 1 | $26 |
| Sanofi | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Intuity Medical Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Merck | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
How this compares
$2,338 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 400 | $427,831 |
| EliquisApixaban | 412 | $322,566 |
| OzempicSemaglutide | 297 | $306,862 |
| Diclofenac Sodium | 696 | $294,701 |
| JardianceEmpagliflozin | 349 | $263,186 |
| JanuviaSitagliptin Phosphate | 228 | $171,167 |
| LinzessLinaclotide | 213 | $114,715 |
| JanumetSitagliptin Phos/Metformin Hcl | 175 | $113,921 |
| Metformin Er GastricMetformin Hcl | 19 | $99,948 |
| MyrbetriqMirabegron | 149 | $78,487 |
| NexiumEsomeprazole Magnesium | 111 | $73,775 |
| TrulicityDulaglutide | 63 | $70,159 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $67,218 |
| EntrestoSacubitril/Valsartan | 77 | $65,721 |
| ProliaDenosumab | 33 | $55,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $112 | $497,990463 claims |
| PfizerEliquis | $44 | $322,566412 claims |
| Novo NordiskOzempic | $69 | $306,862297 claims |
| MerckJanuvia, Janumet | $19 | $285,088403 claims |
| Boehringer IngelheimJardiance, Tradjenta | $18 | $280,383376 claims |
| AstraZenecaNexium, Farxiga, Breztri Aerosphere, Brilinta | $119 | $191,753308 claims |
| AbbVieLinzess, Creon | $353 | $134,302236 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $58 | $104,995182 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $78,487149 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $115 | $70,25348 claims |
| NovartisEntresto | $69 | $65,72177 claims |
| AmgenProlia | $46 | $55,03833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Deal
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.